founded in 2004, erytech is a biopharmaceutical company developing innovative therapies to target unmet medical needs, particularly in the fields of cancer and orphan diseases. erytech’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. encapsulation offers a number of benefits as compared to free-form compounds, reducing the potential for allergic reactions and allowing the therapeutic substance to remain longer in the body. its first product, working by starving tumors, has completed its phase iii development and will provide a therapeutic solution to patients with relapsed and refractory acute lymphoblastic leukemia. the company has a production unit located in lyon with “pharmaceutical establishment” status. it has signed two distribution partnership agreements, with orphan europe-recordati (in europe) and teva (in israel).
Company profile
Ticker
PHXM
Exchange
Website
CEO
Gil Beyen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Erytech Pharma, Erytech Pharma S.A.
SEC CIK
PHXM stock data
Latest filings (excl ownership)
15F-12B
Securities registration termination (foreign)
11 Mar 24
EFFECT
Notice of effectiveness
6 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
POS AM
Prospectus update (post-effective amendment)
4 Mar 24
25
Voluntary exchange delisting
1 Mar 24
6-K
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
21 Feb 24
Transcripts
PHXM
Earnings call transcript
2022 Q3
22 Nov 22
PHXM
Earnings call transcript
2022 Q2
13 Sep 22
PHXM
Earnings call transcript
2022 Q1
13 May 22
PHXM
Earnings call transcript
2021 Q4
14 Mar 22
PHXM
Earnings call transcript
2021 Q3
16 Nov 21
PHXM
Earnings call transcript
2021 Q2
21 Sep 21
PHXM
Earnings call transcript
2020 Q4
9 Mar 21
PHXM
Earnings call transcript
2020 Q3
8 Nov 20
Latest ownership filings
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
23 Dec 22
SC 13G
ARMISTICE CAPITAL, LLC
15 Feb 22
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 22
SC 13G
BIOTECHNOLOGY VALUE FUND L P
10 Mar 21
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
29 Jan 21
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
12 Jan 21
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
13 Oct 20
SC 13D/A
Erytech Pharma S.A.
8 Nov 18
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
1.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 6 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 82.75 mm |
Total shares | 653.01 k |
Total puts | 0.00 |
Total calls | 400.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 517.24 k | $0.00 |
JustInvest | 24.27 k | $18.69 mm |
Baader Bank | 24.00 k | $14.72 mm |
Mariner | 23.90 k | $18.41 mm |
SNEX StoneX | 17.30 k | $13.00 k |
Citadel Advisors | 16.61 k | $12.12 mm |
Millennium Management | 12.07 k | $8.81 mm |
Group One Trading | 10.59 k | $7.73 mm |
Asset Dedication | 4.00 k | $4.00 k |
Ikarian Capital | 3.02 k | $2.26 mm |